Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)-ketamine in the treatment of depression and neuropathic pain
US-2025319092-A1 · Oct 16, 2025 · US
Cooper Health System patents
Cooper Health System holds 6 patents in our database, with recent filings and technology areas summarized below.
| Metric | Value |
|---|---|
| Total patents | 6 |
| Recent patents | 1 |
| First publication | Feb 23, 2017 |
| Latest publication | Oct 16, 2025 |
Filing trend
Year-over-year patent counts for this assignee.
Recent patents
Latest publications where this party is an assignee.
Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)-ketamine in the treatment of depression and neuropathic pain
US-2020360393-A1 · Nov 19, 2020 · US
Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
US-2018098993-A1 · Apr 12, 2018 · US
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
US-9867830-B2 · Jan 16, 2018 · US
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
US-9650352-B2 · May 16, 2017 · US
Notable patents
Representative or frequently cited publications from precomputed assignee stats.
Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)-ketamine in the treatment of depression and neuropathic pain
US-2025319092-A1 · Oct 16, 2025 · US
Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)-ketamine in the treatment of depression and neuropathic pain
US-2020360393-A1 · Nov 19, 2020 · US
Use of (2r, 6r)-hydroxynorketamine, (s)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (r,s)- ketamine in the treatment of depression and neuropathic pain
US-2018098993-A1 · Apr 12, 2018 · US
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
US-9867830-B2 · Jan 16, 2018 · US
Use of (2R, 6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain
US-9650352-B2 · May 16, 2017 · US
Technology areas
Mapped technology topics for this assignee.
| Technology | Patents |
|---|---|
| Human Necessities | 6 |
| Chemistry & Metallurgy | 6 |
Frequently asked questions
Answers are generated from the same data shown on this page.
- How many patents does Cooper Health System have in patentsdb?
- Cooper Health System is linked to 6 publications as assignee in our database.
- What technology areas does Cooper Health System patent most?
- Top mapped technology areas by patent count: Human Necessities (6); Chemistry & Metallurgy (6).
- Is Cooper Health System's patent activity growing?
- In our data, assignee counts were 1 in 2020 and 1 in 2025 (similar year over year).
- What are recent patents assigned to Cooper Health System?
- See the “Recent patents” section above for the latest 5 publications we attribute to this assignee.